Cargando…
All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma
Renal cell carcinoma (RCC) is the most common malignancy of the kidney, representing 80–90% of renal neoplasms, and is associated with a five-year overall survival rate of approximately 74%. The second most common site of metastasis is bone. As patients are living longer due to new RCC targeting age...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551072/ https://www.ncbi.nlm.nih.gov/pubmed/34745857 http://dx.doi.org/10.1016/j.jbo.2021.100399 |